Cargando…
Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
New therapeutic options in breast cancer have improved survival but consequently increase the relevance of late complications. Ovarian suppression/ablation and aromatase inhibitors (AI) in the adjuvant setting have improved outcome, but have clinically important adverse effects on bone health. Howev...
Autores principales: | Lester, J E, Dodwell, D, Horsman, J M, Mori, S, Coleman, R E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361086/ https://www.ncbi.nlm.nih.gov/pubmed/16317429 http://dx.doi.org/10.1038/sj.bjc.6602892 |
Ejemplares similares
-
Strengthening clinical cancer research in the United Kingdom
por: Stead, M, et al.
Publicado: (2011) -
Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
por: Lester, J.E., et al.
Publicado: (2012) -
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
por: Jones, A L, et al.
Publicado: (2009) -
Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom
por: Radford, C F, et al.
Publicado: (2012) -
Cost of managing women presenting with stage IV breast cancer in the United Kingdom
por: Remák, E, et al.
Publicado: (2004)